151 related articles for article (PubMed ID: 21718647)
1. [CYLD deubiquitinase as a recurrent target in oncogenic processes].
Bonnet M; Courtois G
Med Sci (Paris); 2011; 27(6-7):626-31. PubMed ID: 21718647
[TBL] [Abstract][Full Text] [Related]
2. Mild phenotype of familial cylindromatosis associated with an R758X nonsense mutation in the CYLD tumour suppressor gene.
Oiso N; Mizuno N; Fukai K; Nakagawa K; Ishii M
Br J Dermatol; 2004 Nov; 151(5):1084-6. PubMed ID: 15541090
[TBL] [Abstract][Full Text] [Related]
3. CYLD: a deubiquitination enzyme with multiple roles in cancer.
Massoumi R
Future Oncol; 2011 Feb; 7(2):285-97. PubMed ID: 21345146
[TBL] [Abstract][Full Text] [Related]
4. A case of Brooke-Spiegler syndrome with a novel mutation in the CYLD gene in a patient with aggressive non-Hodgkin's lymphoma.
Hunstig F; Schulz S; Nieten I; Froster U; Boltze C; Schliemann S; Hochhaus A; La Rosée P
J Cancer Res Clin Oncol; 2016 Apr; 142(4):845-8. PubMed ID: 26660106
[TBL] [Abstract][Full Text] [Related]
5. CYLD: a tumor suppressor deubiquitinase regulating NF-kappaB activation and diverse biological processes.
Sun SC
Cell Death Differ; 2010 Jan; 17(1):25-34. PubMed ID: 19373246
[TBL] [Abstract][Full Text] [Related]
6. Large germline deletions of the CYLD gene in patients with Brooke-Spiegler syndrome and multiple familial trichoepithelioma.
Vanecek T; Halbhuber Z; Kacerovska D; Martinek P; Sedivcova M; Carr RA; Slouka D; Michal M; Kazakov DV
Am J Dermatopathol; 2014 Nov; 36(11):868-74. PubMed ID: 25347032
[TBL] [Abstract][Full Text] [Related]
7. Trichoepithelioma.
Johnson H; Robles M; Kamino H; Walters RF; Lee A; Sanchez M
Dermatol Online J; 2008 Oct; 14(10):5. PubMed ID: 19061604
[TBL] [Abstract][Full Text] [Related]
8. Phenotype-genotype correlations for clinical variants caused by CYLD mutations.
Nagy N; Farkas K; Kemény L; Széll M
Eur J Med Genet; 2015 May; 58(5):271-8. PubMed ID: 25782638
[TBL] [Abstract][Full Text] [Related]
9. Cyld inhibits tumor cell proliferation by blocking Bcl-3-dependent NF-kappaB signaling.
Massoumi R; Chmielarska K; Hennecke K; Pfeifer A; Fässler R
Cell; 2006 May; 125(4):665-77. PubMed ID: 16713561
[TBL] [Abstract][Full Text] [Related]
10. The CYLD p.R758X worldwide recurrent nonsense mutation detected in patients with multiple familial trichoepithelioma type 1, Brooke-Spiegler syndrome and familial cylindromatosis represents a mutational hotspot in the gene.
Farkas K; Deák BK; Sánchez LC; Martínez AM; Corell JJ; Botella AM; Benito GM; López RR; Vanecek T; Kazakov DV; Kromosoeto JN; van den Ouweland AM; Varga J; Széll M; Nagy N
BMC Genet; 2016 Feb; 17():36. PubMed ID: 26861065
[TBL] [Abstract][Full Text] [Related]
11. [Multiple familial trichoepithelioma: a new CYLD gene mutation].
Duparc A; Lasek-Duriez A; Wiart T; Duban-Bedu B; Gosset P; Modiano P
Ann Dermatol Venereol; 2013 Apr; 140(4):274-7. PubMed ID: 23567228
[TBL] [Abstract][Full Text] [Related]
12. [Aspirin against cylindromatosis? Molecular functions of the CYLD tumor suppressor].
Funk JO
Hautarzt; 2004 Mar; 55(3):327-8. PubMed ID: 15029443
[No Abstract] [Full Text] [Related]
13. Expression of CYLD, NF-kappaB and NF-kappaB-related factors in salivary gland tumors.
Fukuda M; Fukuda F; Horiuchi Y; Oku Y; Suzuki S; Kusama K; Sakashita H
In Vivo; 2006; 20(4):467-72. PubMed ID: 16900776
[TBL] [Abstract][Full Text] [Related]
14. Down-regulation of CYLD as a trigger for NF-κB activation and a mechanism of apoptotic resistance in hepatocellular carcinoma cells.
Urbanik T; Köhler BC; Boger RJ; Wörns MA; Heeger S; Otto G; Hövelmeyer N; Galle PR; Schuchmann M; Waisman A; Schulze-Bergkamen H
Int J Oncol; 2011 Jan; 38(1):121-31. PubMed ID: 21109933
[TBL] [Abstract][Full Text] [Related]
15. Five new CYLD mutations in skin appendage tumors and evidence that aspartic acid 681 in CYLD is essential for deubiquitinase activity.
Almeida S; Maillard C; Itin P; Hohl D; Huber M
J Invest Dermatol; 2008 Mar; 128(3):587-93. PubMed ID: 17851586
[TBL] [Abstract][Full Text] [Related]
16. A novel missense mutation of the CYLD gene identified in a Hungarian family with Brooke-Spiegler syndrome.
Nagy N; Farkas K; Kinyo A; Nemeth IB; Kis E; Varga J; Bata-Csorgo Z; Kemeny L; Szell M
Exp Dermatol; 2012 Dec; 21(12):967-9. PubMed ID: 23171463
[TBL] [Abstract][Full Text] [Related]
17. A recurrent R936X mutation of CYLD gene in a Chinese family with multiple familial trichoepithelioma.
Zhang QG; Liang YH
Indian J Dermatol Venereol Leprol; 2015; 81(2):192-4. PubMed ID: 25751345
[No Abstract] [Full Text] [Related]
18. Tropomyosin Receptor Antagonism in Cylindromatosis (TRAC), an early phase trial of a topical tropomyosin kinase inhibitor as a treatment for inherited CYLD defective skin tumours: study protocol for a randomised controlled trial.
Cranston A; Stocken DD; Stamp E; Roblin D; Hamlin J; Langtry J; Plummer R; Ashworth A; Burn J; Rajan N
Trials; 2017 Mar; 18(1):111. PubMed ID: 28270164
[TBL] [Abstract][Full Text] [Related]
19. CYLD in ubiquitin signaling and tumor pathogenesis.
Ikeda F; Dikic I
Cell; 2006 May; 125(4):643-5. PubMed ID: 16713556
[TBL] [Abstract][Full Text] [Related]
20. Phenotype variability in tumor disorders of the skin appendages associated with mutations in the CYLD gene.
Parren LJMT; Giehl K; van Geel M; Frank J
Arch Dermatol Res; 2018 Sep; 310(7):599-606. PubMed ID: 29974194
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
